Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06584552




Registration number
NCT06584552
Ethics application status
Date submitted
21/08/2024
Date registered
5/09/2024

Titles & IDs
Public title
LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
Scientific title
Lactobacillus Paracasei LPB27 On Early Childhood Eczema
Secondary ID [1] 0 0
2024001_LaCE
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Eczema 0 0
Allergy 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Lactobacillus Paracasei LPB27
Other interventions - Maltodextrin

Experimental: Lactobacillus Paracasei LPB27 - Formulation: Lactobacillus paracasei LPB27 (10 billion cfu/ serve) and Maltodextrin (up to 1g).

Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.

Placebo comparator: Maltodextrin - Formulation: Maltodextrin 1g

Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.


Treatment: Other: Lactobacillus Paracasei LPB27
Probiotic

Other interventions: Maltodextrin
Placebo
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of patients achieving treatment success
Timepoint [1] 0 0
Between baseline and 12 weeks
Secondary outcome [1] 0 0
Mean change in SCORAD index
Timepoint [1] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [2] 0 0
First use of rescue medication
Timepoint [2] 0 0
From baseline to time of starting rescue medication (up to 12 weeks)
Secondary outcome [3] 0 0
Mean change in RECAP
Timepoint [3] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [4] 0 0
Mean change in IDQOL
Timepoint [4] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [5] 0 0
Mean change in EASI
Timepoint [5] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [6] 0 0
Mean change in IGA
Timepoint [6] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [7] 0 0
Mean change in POEM
Timepoint [7] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [8] 0 0
Use of topical corticosteroids
Timepoint [8] 0 0
From baseline to 12 weeks
Secondary outcome [9] 0 0
Mean change in TOPICOP score
Timepoint [9] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [10] 0 0
Mean change in gut microbiota
Timepoint [10] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Secondary outcome [11] 0 0
Mean change in skin microbiota
Timepoint [11] 0 0
From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

Eligibility
Key inclusion criteria
* Age: 3 months to 3 years old
* Diagnosis: Eczema (atopic dermatitis) diagnosed clinically by a paediatric dermatologist or immunologist.
* Severity: Investigator Global Assessment for Atopic Dermatitis (IGA) severity of 1-3 (almost clear, mild, moderate) and a SCORAD score greater than 8.7.
* Willingness and ability of the subject to comply with the protocol requirements.
Minimum age
3 Months
Maximum age
3 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients on systemic immunosuppression and/or biologic agents (participants who start systemic immunosuppression and/or biologic agents mid-way through the study will be considered to have not achieved treatment success and will be withdrawn, regardless of their SCORAD index scores).
* Mothers who are breastfeeding and on probiotics but not willing to stop probiotics.
* Child already on probiotics and parents not willing to stop during the entire study period (washout period of 4 weeks; including formulas that contains probiotics).
* Eczema complicated by active skin infection e.g. impetigo/cellulitis/ eczema herpeticum (can be considered once active infection resolved).
* Child currently on oral or IV antibiotics (washout period of 4 weeks allowable once antibiotics completed). Participants who require antibiotics after being enrolled in the study may continue on the study as usual.
* Immunodeficient disorders.
* Chronic disorder involving the gastrointestinal tract (e.g., inflammatory bowel disease, short gut syndrome, cystic fibrosis).
* Known hypersensitivity to components contained in study product.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/09/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2026
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
2038 - Sydney

Funding & Sponsors
Primary sponsor type
Other
Name
The University of New South Wales
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Evolution Health Pty Ltd
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Keith CY Ooi
Address 0 0
University of New South Wales
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Keith CY Ooi
Address 0 0
Country 0 0
Phone 0 0
9382 1752
Fax 0 0
Email 0 0
keith.ooi@unsw.edu.au
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06584552